Related Experiment Video
Updated: Aug 9, 2026
09:23
Using Extraordinary Optical Transmission to Quantify Cardiac Biomarkers in Human Serum
Published on: December 13, 2017
6.3K
A MoS2 nanosheet-based CRISPR/Cas12a biosensor for efficient miRNA quantification for acute myocardial infarction
1Department of Critical Care Medicine, Affiliated Hospital of Guangdong Medical University, Zhanjiang, 524000, PR China; School of Biomedical Engineering, Southern Medical University, Guangzhou, 510515, PR China.
Biosensors & Bioelectronics
|February 16, 2024
Summary
This study introduces a novel biosensor for detecting microRNA-499, a key marker for acute myocardial infarction (AMI). The antibody-free sensor uses molybdenum disulfide nanosheets and CRISPR/Cas12a technology for rapid and sensitive detection of AMI.
Area of Science:
- Biotechnology
- Nanotechnology
- Molecular Diagnostics
Background:
- Acute myocardial infarction (AMI) is a leading cause of global cardiovascular mortality.
- Timely detection of AMI biomarkers is crucial for effective treatment.
- Current protein markers have limitations, necessitating improved diagnostic approaches.
Purpose of the Study:
- To develop a sensitive, antibody-free, and convenient sensing strategy for AMI detection.
- To utilize CRISPR/Cas12a and molybdenum disulfide (MoS2) nanosheets for enhanced signal amplification.
- To detect miR-499, a superior biomarker for acute myocardial infarction.
Main Methods:
- Construction of a MoS2 nanosheet-powered CRISPR/Cas12a sensing platform.
- Utilizing DNA-based molecular engineering for signal amplification.
- Characterization of MoS2 nanosheets using AFM and TEM.
- Verification of detection via PAGE and fluorescence measurements.
Main Results:
- Sensitive determination of miR-499 with a detection limit of 381.78 pM.
- Linear detection range established from 0.1 nM to 13.33 nM.
- Rapid detection achieved in approximately 30 minutes.
- Successful miRNA detection in human serum with high recovery rates (89.5%-97.6%).
Conclusions:
- The developed MoS2 nanosheet-based CRISPR/Cas12a system offers a highly sensitive and rapid fluorescence sensor for AMI-related miRNA.
- This approach provides an antibody-free, signal-amplified method for biomarker detection.
- The sensor shows potential for clinical diagnosis of acute myocardial infarction.
